Cart
sales@molnova.com
CDK9-IN-4d
CAS No. 2105956-51-0
CDK9-IN-4d( —— )
Catalog No. M13347 CAS No. 2105956-51-0
CDK9-IN-1 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 258 | Get Quote |
|
| 10MG | 410 | Get Quote |
|
| 25MG | 678 | Get Quote |
|
| 50MG | 954 | Get Quote |
|
| 100MG | 1287 | Get Quote |
|
| 500MG | 2574 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCDK9-IN-4d
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK9-IN-1 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition.
-
DescriptionCDK9-IN-1 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition; blocks the cell cycle both in G0/G1 and G2/M phase to prevent the proliferation and differentiation of cancer cells; significantly suppresses cancer with low toxicity in mice bared-breast cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2105956-51-0
-
Formula Weight569.641
-
Molecular FormulaC31H32FN7O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5.2 mg/mL (9.13 mM)
-
SMILESFC1=CC=C(NC(C2(CC2)C(NC3=CC=C(NC4=NC=C5C(N(C6CCCC6)C(C(N(C)C)=O)=C5)=N4)C=C3)=O)=O)C=C1
-
Chemical NameN-(4-((7-cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li Y, et al. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3231-3237.
molnova catalog
related products
-
VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
-
ML133 HCl
ML133 HCl is a selective potassium channel inhibitor for Kir2.1 with IC50 of 1.8 μM (pH 7.4) and 290 nM (pH 8.5), has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.
-
CDK9-IN-1
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
